Dosing began at Weill Cornell Medical Center in a Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS.

In people with benign MS, there is a loss of overall brain tissue but other parts of the brain may grow to help compensate for the damage, a study suggests.

Inflammatory-type lesions and myelopathies found on MRI were significantly associated with attribution of neuropsychiatric events to systemic lupus erythematosus. Magnetic resonance imaging (MRI) ...